Company: PTHS
Filing Date: 2025-05-27
Form Type: DEFM14C
Source: 0001140361-25-020509
Chunk: 300

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-05-27
Form: DEFM14C
Chunk 300
---
 Channel does not intend to file patents for these processes but will keep the detailed protocols (e.g., the selected crystallization solvent or the particular salt) as trade secrets. Channel has developed the formulation for the eye drops associated with the eye pain treatment therapy and depot injections associated with the nerve block therapy and are in the early stages of determining its manufacturing strategy. Channel expects to pursue a similar strategy to have CT2000 and CT3000 manufactured by CMOs.

167

#### TABLE OF CONTENTS

#### Intellectual Property
Protection of Channel’s intellectual property is an important part of its business. Channel seeks patent protection in the United States and in other countries for its inventions and discoveries, and Channel develops and protects its key know-how and trade secrets relating to its platform technology and the products Channel is developing using its platform.

Channel has adopted a strategy of seeking patent protection in the United States and in other jurisdictions globally that Channel deems appropriate with respect to certain of its technologies relating to its products and process. Channel has been granted a patent in the United States directed to the composition of matter and use of its lead compound, CC8464. Channel has also obtained patents in France, Japan, India in Mexico, Israel and South Korea. Its U.S. patent for CC8464 will expire in 2035. In addition, Channel has an additional pending patent application in India.

Channel has pending patent applications for each of CT2000 ophthalmic formulation and CT3000 injectable formulations, and for the treatment of pain.

Granted U.S. Patent 9,855,234 is directed to the diclofenac spray formulation and will expire in April of 2036. The Ondansetron Spray Formulation is covered by U.S. Patent 9,566,233 and U.S. Patent 10,172,833. Both patents are composition-of-matter patents that will expire in May 2034 and August 2036, respectively. The U.S. and international patents relating to the Rizatriptan Spray Formulation have either expired or have been abandoned.

In addition to patents and licenses, Channel relies on trade secrets and know-how to develop and maintain technologies and methods that provide it a meaningful competitive advantage. However, trade secrets can be difficult to defend and maintain. Channel seeks to protect its proprietary technology and processes, and maintain ownership of certain technologies, in part, through confidentiality agreements and invention assignment agreements with its employees, consultants and commercial partners.

#### Channel’s Competition
The biotechnology and pharmaceutical industries are highly